Benjamin Tomlinson is an Oncology physician affiliated with University Hospitals Seidman Cancer Center. OpenAlex indexes 143 publications with 1,982 citations (h-index 24); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11100 Euclid Ave
Cleveland, OH 441061716
Telephone
216-844-3951Provider last certified this registry record 12 Jan 2021.
Clinical trials
- Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
Sponsor: Benjamin Tomlinson
- Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
Sponsor: Benjamin Tomlinson
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
32 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Research & Development, LLCProgram year20251 payment
- GENZYME CORPORATIONProgram year20253 payments
- BeOne Medicines USA, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
37.8%BCL-2 Inhibitor15.8%Venclexta100%Part D≥28 patientsKinase inhibitor10.5%Jakafi44%Brukinsa39%Imbruvica18%Part D<11 patients+ 4 more classes in this area
Dermatology
13.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor13.9%Acyclovir100%Part D≥36 patientsNervous system
13.7%Phenothiazine9.3%Prochlorperazine Maleate100%Part D≥33 patientsGabapentinoids2.4%Gabapentin100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>
Journal of Clinical Oncology
2024 - Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Afshin Dowlati, MD
University Hospitals Seidman Cancer Center
Daniel Spratt, MD
University Hospitals Seidman Cancer Center
Theodoros Teknos, MD
University Hospitals Seidman Cancer Center
Joseph Bokar, MD
University Hospitals Seidman Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”